focus -WSS

focus

author：entertainment 2025-10-01 21:36:54 - browse：1675

U.S. President Joe Biden stands with his fingers locked next to an US flag — politics coverage from STAT — President Biden's White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs.

WASHINGTON — The White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs, its latest effort to draw attention to the program in an election year.

The news is not controversial: The pharmaceutical companies that make the first ten drugs up for negotiation all submitted counteroffers. It’s an incremental step in the new program, which was created in 2022.

Earlier this year, Medicare sent its initial price offers to the companies. Neither the Biden administration nor the drug manufacturers have volunteered any information about the White House’s initial price offers or the counteroffers. The process is scheduled to end by Aug. 1.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： How to protect coverage of PrEP

entertainment

WSS

Doctors have an ethical obligation to be advocates

Will the FTC rein in IQVIA's health data empire?

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Novartis develops a rapidly manufactured CAR

CDC Director Mandy Cohen on transparency, trust, and health

knowledge

focus

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

New lawsuit accuses health insurer Cigna of denying claims in bulk

Tori Bowie and the unacceptable rates of Black maternal death

Inside the culture of fear in the White House science office of Eric Lander

How one medical school became remarkably diverse

The haunting brain science of long Covid

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why patients can’t get everything they want on drug pricing

The high cost of giving birth even with insurance

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

hotspot

Inside the culture of fear in the White House science office of Eric Lander

What to watch for from Zogenix and Amicus clinical trials

Burning questions about Delta and the next phase of the Covid pandemic

Severe heat forecast: Where scorching temperatures will persist over the next week

Roche’s Alnylam deal shows drug firms interested in heart drugs

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

knowledge

leisure time

entertainment

focus